Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K
Department of Rehabilitation Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.
Bone. 2002 Jul;31(1):114-8. doi: 10.1016/s8756-3282(02)00783-4.
Significant reduction in bone mineral density (BMD) occurs in patients with Parkinson's disease (PD), correlating with immobilization and with vitamin D deficiency, and increasing the risk of hip fracture, especially in elderly women. As a biological indicator of compromised vitamin K status, an increased serum concentration of undercarboxylated osteocalcin (Oc) has been associated with reduced BMD in the hip and an increased risk of fracture in otherwise healthy elderly women. We evaluated treatment with vitamin K(2) (menatetrenone; MK-4) in maintaining BMD and reducing the incidence of nonvertebral fractures in elderly female patients with PD. In a random and prospective study of PD patients, 60 received 45 mg of MK-4 daily for 12 months, and the remaining 60 (untreated group) did not. At baseline, patients of both groups showed vitamin D and K(1) deficiencies, high serum levels of ionized calcium, and glutaminic residue (Glu) Oc, and low levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25-(OH)(2)D], indicating that immobilization-induced hypercalcemia inhibits renal synthesis of 1,25-(OH)(2)D and compensatory PTH secretion. BMD in the second metacarpals increased by 0.9% in the treated group and decreased by 4.3% in the untreated group (p < 0.0001). Vitamin K(2) level increased by 259.8% in the treated group. Correspondingly, significant decreases in Glu Oc and calcium were observed in the treated group, in association with an increase in both PTH and 1,25-(OH)(2)D. Ten patients sustained fractures (eight at the hip and two at other sites) in the untreated group, and one hip fracture occurred among treated patients (p = 0.0082; odds ratio = 11.5). The treatment with MK-4 can increase the BMD of vitamin D- and K-deficient bone by increasing vitamin K concentration, and it can also decrease calcium levels through inhibition of bone resorption, resulting in an increase in 1,25-(OH)(2)D concentration.
帕金森病(PD)患者骨矿物质密度(BMD)显著降低,这与制动及维生素D缺乏相关,增加了髋部骨折风险,在老年女性中尤为明显。作为维生素K状态受损的生物学指标,血清中羧化不全骨钙素(Oc)浓度升高与髋部骨密度降低及健康老年女性骨折风险增加有关。我们评估了维生素K₂(甲萘醌四烯甲萘醌;MK-4)治疗对维持老年女性PD患者骨密度及降低非椎体骨折发生率的作用。在一项针对PD患者的随机前瞻性研究中,60例患者每日接受45mg MK-4治疗,为期12个月,其余60例(未治疗组)未接受治疗。基线时,两组患者均存在维生素D和K₁缺乏、血清离子钙及谷氨酰胺残基(Glu)Oc水平升高,甲状旁腺激素(PTH)和1,25-二羟维生素D[1,25-(OH)₂D]水平降低,表明制动诱导的高钙血症抑制了肾脏合成1,25-(OH)₂D及代偿性PTH分泌。治疗组第二掌骨骨密度增加了0.9%,未治疗组降低了4.3%(p<0.0001)。治疗组维生素K₂水平升高了259.8%。相应地,治疗组Glu Oc和钙显著降低,同时PTH和1,25-(OH)₂D均升高。未治疗组有10例患者发生骨折(8例髋部骨折,2例其他部位骨折),治疗组有1例髋部骨折(p=0.0082;比值比=11.5)。MK-4治疗可通过提高维生素K浓度增加维生素D和K缺乏骨骼的骨密度,还可通过抑制骨吸收降低钙水平,导致1,25-(OH)₂D浓度升高。